Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor
Advanced Science · 2026
DOI: 10.1002/advs.76025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Ting Cao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Polycomb Repressive Complex 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology (MOST) of China, National Natural Science Foundation of China, "Pioneer" and "Leading Goose" R&D Program of Zhejiang.
Abstract (Originalsprache)
Polycomb Repressive Complex 2 (PRC2), containing homologous EZH1 or EZH2 as the catalytic subunit, is a conserved methyltransferase complex that represses gene transcription by transferring methyl group from SAM to H3K27. Gain‐of‐function mutations of EZH2 and aberrant H3K27 methylation have been linked to human cancers. SAM‐competitive EZH1 and EZH2 dual inhibitors have been approved by the FDA for treating B‐cell lymphoma and other cancers. Here, we characterized a small molecule C36, which potently inhibits EZH2/PRC2, but not EZH1/PRC2, with a novel SAM non‐competitive mechanism. Cryo‐EM structures revealed that C36 binds to a pocket at the interface of SET‐Activation‐Loop (SAL), stimulation‐responsive motif (SRM), and I‐SET domain of EZH2, and WD40 domain of EED. C36 binding induces conformational changes and disrupts allosteric communication between EZH2 and ligand‐bound EED. C36 efficiently inhibits H3K27 trimethylation and PRC2 target gene expression in tumor cells and xenograft tumors with low hematotoxicity. Multi‐omics analyses employing C36 uncovered the direct regulation of IFNB1 by EZH2/PRC2. The combined treatment of syngeneic LLC lung cancer with C36 and a PD‐1 antibody significantly enhances anti‐tumor efficacy. Our study identifies a new allosteric mechanism of PRC2 inhibition and paves the way for the development of highly selective EZH2/PRC2 inhibitors for combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- Westlake Laboratory of Life Sciences and Biomedicine, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
- New Cornerstone Science Laboratory, Westlake University, Hangzhou, Zhejiang, China.
- Shanghai Clinical Research and Trial Center, Shanghai, China.
- Lingang Laboratory, Shanghai, China.
ORCID-Profile: Dongdong Liu
Förderung
- Ministry of Science and Technology (MOST) of China
- National Natural Science Foundation of China
- "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- New Cornerstone Investigator Program
- Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University
Zitieren
APA
Cao, T., Liu, D., Gao, H., Qin, C., Zhang, W., Lu, Z., Tan, D., Qu, Y., Liu, Y., Zou, Z., Yu, H., & Qi, W. (2026). Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor. Advanced Science. https://doi.org/10.1002/advs.76025
Vancouver
Cao T, Liu D, Gao H, Qin C, Zhang W, Lu Z, et al. Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor. Advanced Science. 2026. doi:10.1002/advs.76025
BibTeX
@article{Cao2026,
author = {Cao, Ting and Liu, Dongdong and Gao, Haishan and Qin, Chenyang and Zhang, Wen and Lu, Ziyun and Tan, Dongxia and Qu, Yuxiu and Liu, Yusong and Zou, Zhiran and Yu, Hongtao and Qi, Wei},
title = {Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76025}
}
EUVIMED